The Indian Medical Parliamentarians Forum (IMPF) - a cross-party group of 45 MPs who are also medical professionals -- has sought uninterrupted access to Enzyme Replacement Therapy for children ...
The Indian Medical Parliamentarians’ Forum (IMPF), a cross-party collective of 45 medical professionals turned ...
Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...
A couple struggling to access to a vital cancer treatment say they are are "extremely stressed" by the uncertainty in its ...
Zacks Investment Research on MSN
Denali enters into a $275M funding deal with Royalty Pharma
Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback